Vital

Side effects

Ozempic Hair Loss: Why Shedding Happens and When It Stops

Hair shedding during GLP-1 weight loss is usually telogen effluvium, a delayed and temporary response to rapid weight loss. Here is what the labels report, the usual timeline, and what to check with your provider.

Last reviewed

The Vital angle

Telogen effluvium shows up months after the trigger, so the useful question is what your weight did two to four months before the shedding started. Vital puts your dose history next to weight trends from Apple Health, which makes that timeline easy to see and share with your prescriber.

What Ozempic hair loss usually is

Most reports of Ozempic hair loss describe more hair in the brush, the drain, or on the pillow, often a few months into treatment. The pattern most studies point to is telogen effluvium: a period of extra shedding that follows a stress on the body, such as fast weight loss. The American Academy of Dermatology (AAD) lists weight loss of 20 pounds or more as one trigger. It describes this kind of shedding as normal and temporary.

That matters because the shedding can look alarming. A normal day already includes about 50 to 100 shed hairs, according to the AAD. During telogen effluvium, many more hairs move into the resting and shedding phase at the same time, so the change is easy to notice.

What the labels and studies report

The prescribing information connects hair loss to weight loss, not to a direct effect on hair that the trials could measure.

  • Wegovy® 2.4 mg: hair loss in 3.3 percent of people versus 1 percent on placebo. The label says these reports were associated with weight reduction. Rates were higher in women (4 percent) than in men (0.9 percent).
  • Wegovy 7.2 mg: hair loss in 5.8 percent of people, with 8.4 percent of women.
  • Zepbound®: hair loss in 4 to 5 percent of people across doses, versus 1 percent on placebo.

Ozempic® at diabetes doses lists alopecia among postmarketing reports, without a trial rate.

Outside the trials, a 2026 systematic review of 24 studies found that semaglutide and tirzepatide had the highest reported rates of hair loss among GLP-1 medications. Women appeared to be affected more often, and the authors named rapid weight loss as a potential contributor. A 2026 cohort study of TriNetX health records found higher odds of telogen effluvium with semaglutide and tirzepatide, and lower body mass index at follow-up in people who had hair loss. The authors suggested that the physiologic stress of weight loss may contribute. These are observational studies, so they show a link but not proof of cause.

The usual timeline

Telogen effluvium runs on a delay, which is why it can feel disconnected from the cause.

  1. The trigger. Rapid weight loss, a large drop in food intake, illness, or major stress pushes more hairs into the resting phase.
  2. The lag. The AAD says most people notice the extra shedding a few months after the trigger. For GLP-1 users, that can fall in the first months of treatment, when weight loss is often fastest.
  3. The shedding phase. Extra shedding continues for a while. It is often most visible when you wash or brush your hair.
  4. Recovery. The AAD says hair tends to regain its normal fullness within six to nine months. If the stress continues, shedding can last longer.

Hair grows slowly, so new growth takes time to show. Short new hairs along the hairline are often the first sign of recovery.

Nutrition gaps that can add to shedding

Hair follicles are active tissue that needs a steady supply of protein, energy, and micronutrients. On a GLP-1, intake can drop a long way below what it was.

The 2025 joint nutrition advisory from four obesity and nutrition societies warns that very low intakes, especially below about 1,200 calories a day for women and 1,800 for men, raise the risk of nutrient shortfalls. It lists iron, zinc, calcium, magnesium, and vitamins A, D, E, K, B1, B12, and C as nutrients of concern. It also names excessive hair loss among the signs of a true deficiency, along with unusual fatigue, muscle weakness, poor wound healing, and easy bruising.

Practical steps that support hair without guesswork:

  • Keep protein in every meal. A small appetite makes this hard, but it is the part you can control. The protein on GLP-1 guide has targets and small-meal ideas.
  • Avoid crash restriction on top of the medication. Stacking a very low-calorie diet onto appetite suppression speeds weight loss and raises the risk of nutrient gaps.
  • Eat varied foods when you can. Eggs, fish, meat, legumes, dairy, nuts, seeds, fruit, and vegetables cover most of the nutrients of concern.
  • Ask before high-dose supplements. A standard multivitamin is a common suggestion, but high doses of some nutrients can cause problems. Ask your provider whether blood tests for iron, vitamin D, B12, or thyroid function make sense for you.

Other causes worth ruling out

Not all hair loss during GLP-1 treatment is telogen effluvium. The systematic review found that androgenetic alopecia (pattern hair loss) was one of the two subtypes reported most often. The AAD also lists other triggers of shedding, such as illness, surgery, and stopping birth control pills. Your provider can check for medical causes such as thyroid problems or low iron.

See a dermatologist or your provider if you notice:

  • Patches of complete hair loss, rather than overall thinning
  • Scalp pain, redness, scaling, or burning
  • Thinning that continues for more than about six months after your weight has stabilized
  • Hair loss with unusual fatigue, feeling cold, or other new symptoms

What not to do

  • Do not change your dose to save your hair. Do not stop, skip, or reduce a dose on your own. Talk to your prescriber, who can weigh the speed of your weight loss against side effects.
  • Do not buy a stack of "hair" supplements first. Telogen effluvium from weight loss usually settles once the trigger settles, so a supplement is not the first step. Biotin is often sold for hair, but the FDA warns that biotin supplements can cause incorrect results on some lab tests. Ask your pharmacist before you start one, and tell your lab if you take it.
  • Do not judge too early. Telogen effluvium takes months to start and months to recover. A two-week change in a hair routine will not show a result.

Questions for your prescriber

Bring a short, factual summary to the visit:

  • When the shedding started, and how much weight you had lost by then
  • How fast your weight dropped in the months before the shedding
  • What a typical day of food and protein looks like now
  • Any other changes, such as illness, surgery, stress, or new medicines

This helps your prescriber decide whether the pace of weight loss, your intake, or another cause needs attention. For other effects to watch, see the GLP-1 side effects guide.


Wegovy®, Ozempic® are trademarks of Novo Nordisk A/S. Zepbound® is a trademark of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Very fast weight loss

    The Wegovy label associates hair loss with weight reduction, and observational studies point to rapid weight loss as a likely contributor to telogen effluvium. The pace of loss is a topic for your prescriber.

  • Crash dieting on top of the medication

    Very low intakes, especially below about 1,200 calories a day for women and 1,800 for men, raise the risk of nutrient shortfalls. Excessive hair loss is one listed sign of true deficiency.

  • Low protein intake

    Hair follicles need a steady supply of protein. A small appetite can push protein far below what the body needs during active weight loss.

  • High-dose biotin before blood tests

    The FDA warns that biotin supplements can cause incorrect results on some lab tests. Ask your pharmacist before you start one, and tell the lab if you take it.

  • Patchy loss, scalp pain, or redness

    These do not fit the usual pattern of telogen effluvium. See a dermatologist or your provider to check for other causes such as alopecia areata, scalp conditions, or thyroid disease.

Frequently asked questions

  • Hair loss is a listed side effect of the higher semaglutide doses used for weight loss. In the Wegovy 2.4 mg trials it was reported in 3.3 percent of people versus 1 percent on placebo, and the label associates it with weight reduction. Most cases look like telogen effluvium, a temporary shedding.

  • Telogen effluvium usually starts a few months after the trigger. For many GLP-1 users that falls in the first months of treatment, when weight loss is often fastest.

  • For telogen effluvium, the American Academy of Dermatology describes the shedding as temporary and says hair tends to regain its normal fullness within six to nine months. If shedding continues longer, see a dermatologist.

  • The Zepbound label reports 4 to 5 percent versus 1 percent on placebo, and a 2026 systematic review found tirzepatide, which is associated with the greatest weight loss, was most often linked to telogen effluvium. The studies are observational, so the comparison is not settled.

  • No single vitamin is proven to stop shedding from weight loss. Adequate protein and a varied diet matter most. Ask your provider whether blood tests for iron, vitamin D, B12, or thyroid function make sense before you start supplements.

  • Do not change, skip, or stop a dose on your own. Talk to your prescriber, who can review the pace of your weight loss, your intake, and other causes.

Sources

  1. Do you have hair loss or hair shedding? · American Academy of Dermatology
  2. Wegovy (semaglutide) Prescribing Information and Medication Guide · Novo Nordisk
  3. Zepbound (tirzepatide) Prescribing Information · Eli Lilly and Company
  4. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling · Science Progress (via NIH / NCBI PMC)
  5. Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study · The Laryngoscope (via PubMed)
  6. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory · Obesity (via NIH / NCBI PMC)

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.